The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma : Emphasis on therapeutic opportunities
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
Mycosis Fungoides (MF) and Sézary Syndrome (SS) belong to a wide spectrum of T cell lymphoproliferative disorders collectively termed cutaneous T cell lymphomas (CTCL). CTCLs represent an archetype of heterogeneous and dynamically variable lymphoproliferative neoplasms typified by distinct clinical, histological, immunophenotypic, and genetic features. Owing to its complex dynamics, the pathogenesis of CTCL remains elusive. However, in recent years, progress in CTCL classification combined with next-generation sequencing analyses has broadened the genetic and epigenetic spectrum of clearly defined CTCL entities such as MF and SS. Several large-scale genome studies have identified the polygenic nature of CTCL and unveiled an idiosyncratic mutational landscape involving genetic aberrations, epigenetic alterations, cell cycle dysregulation, apoptosis, and the constitutive activation of T cell/NF-κB/JAK-STAT signaling pathways. In this review, we summarize the evolving insights on how the intrinsic epigenetic events driven by dysregulated miRNAs, including the oncogenic and tumor-suppressive miRNAs, influence the pathogenesis of MF and SS. We also focus on the interplay between the JAK/STAT pathway and miRNAs in CTCL as well as the significance of the miRNA/STAT axis as a relevant pathogenetic mechanism underlying CTCL initiation and progression. Based on these biologic insights, the current status and recent progress on novel therapies with a strong biological rationale, including miRNA-targeted molecules and JAK/STAT-targeted therapy for CTCL management, are discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
|---|---|
| Enthalten in: |
Seminars in cell & developmental biology - 154(2023), Pt C vom: 15. Feb., Seite 239-249 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patil, Kalyani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cutaneous T cell lymphoma |
|---|
| Anmerkungen: |
Date Revised 21.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.semcdb.2022.09.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347319440 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347319440 | ||
| 003 | DE-627 | ||
| 005 | 20231226033540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semcdb.2022.09.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347319440 | ||
| 035 | |a (NLM)36216715 | ||
| 035 | |a (PII)S1084-9521(22)00287-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patil, Kalyani |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma |b Emphasis on therapeutic opportunities |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Mycosis Fungoides (MF) and Sézary Syndrome (SS) belong to a wide spectrum of T cell lymphoproliferative disorders collectively termed cutaneous T cell lymphomas (CTCL). CTCLs represent an archetype of heterogeneous and dynamically variable lymphoproliferative neoplasms typified by distinct clinical, histological, immunophenotypic, and genetic features. Owing to its complex dynamics, the pathogenesis of CTCL remains elusive. However, in recent years, progress in CTCL classification combined with next-generation sequencing analyses has broadened the genetic and epigenetic spectrum of clearly defined CTCL entities such as MF and SS. Several large-scale genome studies have identified the polygenic nature of CTCL and unveiled an idiosyncratic mutational landscape involving genetic aberrations, epigenetic alterations, cell cycle dysregulation, apoptosis, and the constitutive activation of T cell/NF-κB/JAK-STAT signaling pathways. In this review, we summarize the evolving insights on how the intrinsic epigenetic events driven by dysregulated miRNAs, including the oncogenic and tumor-suppressive miRNAs, influence the pathogenesis of MF and SS. We also focus on the interplay between the JAK/STAT pathway and miRNAs in CTCL as well as the significance of the miRNA/STAT axis as a relevant pathogenetic mechanism underlying CTCL initiation and progression. Based on these biologic insights, the current status and recent progress on novel therapies with a strong biological rationale, including miRNA-targeted molecules and JAK/STAT-targeted therapy for CTCL management, are discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cutaneous T cell lymphoma | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a JAK/STAT pathway | |
| 650 | 4 | |a MiRNAs | |
| 650 | 4 | |a Mycosis Fungoides | |
| 650 | 4 | |a Sézary Syndrome | |
| 650 | 4 | |a Therapeutics | |
| 700 | 1 | |a Sher, Gulab |e verfasserin |4 aut | |
| 700 | 1 | |a Kuttikrishnan, Shilpa |e verfasserin |4 aut | |
| 700 | 1 | |a Moton, Safwan |e verfasserin |4 aut | |
| 700 | 1 | |a Alam, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Buddenkotte, Joerg |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Aamir |e verfasserin |4 aut | |
| 700 | 1 | |a Steinhoff, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Uddin, Shahab |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in cell & developmental biology |d 1998 |g 154(2023), Pt C vom: 15. Feb., Seite 239-249 |w (DE-627)NLM093851685 |x 1096-3634 |7 nnns |
| 773 | 1 | 8 | |g volume:154 |g year:2023 |g number:Pt C |g day:15 |g month:02 |g pages:239-249 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semcdb.2022.09.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 154 |j 2023 |e Pt C |b 15 |c 02 |h 239-249 | ||